Stocks on the move at close (the 1st): MIRAINI HOLDINGS, Science Arts, RICOH COMPANY, and others

MIRAINI HOLDINGS CO., LTD. <546A> - Extended gains for a second straight session. Subsidiary Hagiwara Techno Solutions announced today that it signed an authorized distributor agreement with Avalue Technology, a Taiwanese industrial computer manufacturer. Under the agreement, Hagiwara Techno Solutions acquired distribution rights for Avalue Technology's full product lineup - including embedded computers, industrial PCs, and edge computing devices - across Japan and broader Asia. The two companies plan to deepen collaboration, focusing on smart cities, edge AI, and social infrastructure as key markets to advance industrial digitalization and address societal challenges.

Science Arts, Inc. <4412> - Surged in afternoon trading. The company announced around 11:30 a.m. today that the Nagoya City Disaster Prevention and Crisis Management Bureau adopted about 1,000 IDs of its live communication platform Buddycom, sparking buying interest. Buddycom uses internet networks to enable simultaneous communication among multiple users - similar to walkie-talkies or wireless radios - via a smartphone or tablet app. The platform is used across various industries, including aviation, railways, construction, welfare facilities, and distribution.

RICOH COMPANY, LTD. <7752> - Rose for a ninth consecutive session, hitting a new year-to-date high. The company announced on the 31st that it developed physical AI technology applicable to a wide range of robots, fueling buying interest. The technology leverages a Latent Action Model (LAM) to learn common representations of actions - such as "grasping objects," "moving forward," and "relocating targets" - from video footage of humans and robots performing tasks. RICOH confirmed the technology's effectiveness in a virtual environment and plans to validate it in real-world settings while evaluating applicability to various tasks and environments.

Delta-Fly Pharma, Inc. <4598> - Hit the daily limit-up. After market close on the 31st, the company released interim data from its Phase 2/3 clinical trial in Japan of DFP-17729 (a tumor microenvironment modulator) for patients with unresectable or recurrent/advanced pancreatic cancer receiving third-line or later treatment. No adverse effects affecting trial continuation have been observed to date. Under double-blind conditions, the overall survival rate of all subjects stands at 71.8%, with a median overall survival (OS) of about 7.2 months. Given that median OS for patients with advanced pancreatic cancer receiving third-line or later treatment is generally reported at about 3-4 months, the company said the results suggest potential OS prolongation, though the trial remains ongoing under double-blind conditions and final efficacy evaluations have not been completed.

RACCOON HOLDINGS, Inc. <3031> - Extended gains to set a new year-to-date high. After market close on the 31st, the company reported first-quarter (May-July) consolidated financial results. Net sales rose 13.9% year-on-year to 1,776 million yen, while net profit jumped 31.4% to 226 million yen. Strong performance was driven by expanded promotional investment to grow its customer base, along with a gain on the sale of investment securities. Investors welcomed the results.

Nulab Inc. <5033> - Surged sharply to a new all-time high. After market close on the 31st, the company announced it will support migration from PR TIMES' task management tool Jooto to its own project management tool Backlog, pursuant to an agreement with PR TIMES Corporation <3922>, serving as a positive catalyst. The initiative follows the announcement of the planned discontinuation of Jooto (scheduled for July 31, 2027), targeting users of the service, which counts 2,379 paying corporate clients and over 500,000 users. Nulab noted it will not succeed to the Jooto business or customer contracts, with migration to Backlog based on individual customer applications.

* This article may contain unverified information. All investment decisions should be made at your own discretion and risk.

Source: MINKABU PRESS

*Translated by generative AI. Click here for the original article.